Literature DB >> 2052530

Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers.

H D Ross1, K K Chan, A J Piraino, V A John.   

Abstract

The plasma concentration-time profiles and pharmacokinetics were characterized for nicotine and its major metabolite, cotinine, after multiple daily application of a nicotine user-activated transdermal therapeutic system (UATTS) to nine healthy smokers. The volunteers abstained from smoking 24 hr prior to and during the course of the study. A 10-cm2 system (designed to deliver 75 micrograms/cm2/hr) was applied every 24 hr for 5 days, with serial blood samples taken on Days 1 and 5 and after system removal on Day 5. Generally, the nicotine UATTS was well tolerated. Predose nicotine concentrations on Days 3 to 5 indicated that steady state was reached by Day 3. The nicotine pharmacokinetic parameters for Day 1 and Day 5 were similar: the mean (SD) AUC(0-24) values for Days 1 and 5 were 271.7 (50.7) and 311.7 (55.0) ng.hr/ml, the mean (SD) Cmax values were 16.3 (2.6) and 16.8 (2.9) ng/ml, and the median (range) Tmax values on Days 1 and 5 were 12 (9-24) hr and 12 (0-24) hr, respectively. There was only slight or no accumulation of nicotine after multiple dosing as indicated by the Day 5 to Day 1 AUC and Cmax ratios of 1.15 (0.09) and 0.98 (0.06), respectively. Overall, the UATTS system maintained relatively constant plasma nicotine concentrations and is suitable for once-daily application.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052530     DOI: 10.1023/a:1015810019076

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Transdermal nicotine facilitates smoking cessation.

Authors:  J E Rose; E D Levin; F M Behm; C Adivi; C Schur
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

2.  Clinical and pharmacokinetic properties of a transdermal nicotine patch.

Authors:  S C Mulligan; J G Masterson; J G Devane; J G Kelly
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

3.  Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids.

Authors:  P Jacob; M Wilson; N L Benowitz
Journal:  J Chromatogr       Date:  1981-01-02

4.  [Long-term effects of a combination of transdermal nicotine administration with behavior therapy for smoking cessation].

Authors:  G Buchkremer; H Bents; E Minneker; K Opitz
Journal:  Nervenarzt       Date:  1988-08       Impact factor: 1.214

5.  Plasma nicotine levels after cigarette smoking and chewing nicotine gum.

Authors:  M A Russell; C Feyerabend; P V Cole
Journal:  Br Med J       Date:  1976-05-01

6.  Transdermal nicotine reduces cigarette craving and nicotine preference.

Authors:  J E Rose; J E Herskovic; Y Trilling; M E Jarvik
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

7.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  Transdermal administration of nicotine.

Authors:  J E Rose; M E Jarvik; K D Rose
Journal:  Drug Alcohol Depend       Date:  1984-05       Impact factor: 4.492

9.  Effectiveness of a transdermal nicotine system in smoking cessation studies.

Authors:  T Abelin; R Ehrsam; A Bühler-Reichert; P R Imhof; P Müller; A Thommen; K Vesanen
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-03
  9 in total
  3 in total

1.  Bioavailability and absorption kinetics of nicotine following application of a transdermal system.

Authors:  S K Gupta; N L Benowitz; P Jacob; C N Rolf; J Gorsline
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

2.  Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy.

Authors:  Saul Shiffman; Stuart G Ferguson; Chad J Gwaltney; Mark H Balabanis; William G Shadel
Journal:  Psychopharmacology (Berl)       Date:  2005-11-01       Impact factor: 4.530

Review 3.  Pharmacokinetic characterisation of transdermal delivery systems.

Authors:  B Berner; V A John
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.